In 2025, the American Association of Clinical Endocrinology updated its Obesity Algorithm, which highlights the importance of preserving skeletal muscle during medical weight-loss interventions: patients who retain strength tend to experience fewer side effects, more energy, and better long-term weight maintenance
The evidence base includes STEP (semaglutide for weight management, NEJM 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)
The starting dose of semaglutide was 0.25 mg/week for 2 weeks, followed by 0.5 mg/week for 2 weeks, escalating to 1.0 mg/week for 12 weeks
Reconstitute with 2.0 mL of bacteriostatic water for a 5,000 mcg/mL solution